Deep Track Capital acquired 6,772,595 shares of Alumis (NASDAQ:ALMS) during the first quarter of 2026, an estimated $169.31 million investment based on quarterly average pricing, according to a 15 May SEC filing. The biotechnology company develops therapies for autoimmune and neuroinflammatory diseases. Its lead candidate, envudeucitinib, showed strong Phase 3 psoriasis results with PASI 90 response rates of 68.0% and 62.1% by Week 24. Alumis plans to submit an NDA in the fourth quarter, whilst pivotal Phase 2b lupus data are expected in the third quarter. Alumis shares were trading at $22.02, up 355% over the past year, outperforming the S&P 500's 28% gain. The company held $569.5 million in cash as of quarter-end, sufficient to fund operations into the fourth quarter of 2027.

Omega Fund Management sold 411,968 shares of Alumis in the first quarter, reducing its stake to 241,255 shares, according to an SEC filing. The transaction was valued at approximately $10.3 million based on quarterly average pricing. Despite the sale, Alumis remains a meaningful holding for Omega at 3.3% of assets under management. The move appears to be profit-taking following Alumis shares' 327% gain over the past year, significantly outperforming the S&P 500's roughly 25% increase. Alumis, a clinical-stage biotechnology company developing therapies for autoimmune diseases, recently reported positive late-stage psoriasis data for its lead TYK2 inhibitor candidate. The company plans an FDA submission in the fourth quarter and ended the quarter with $569.5 million in cash, sufficient to fund operations into late 2027.

ACT Capital Management has acquired 174,250 shares of Alumis for approximately $4.36 million, establishing a new position representing 3.02% of its assets under management, according to an SEC filing dated 8 May 2026. The clinical-stage biotechnology company focuses on autoimmune and neuroinflammatory disorders, with lead candidates targeting TYK2 inhibition. Alumis shares have surged 350% over the past year to $23.76, driven by positive Phase 3 data showing 65% of patients achieving PASI 90 skin clearance in plaque psoriasis trials. The company plans to submit a new drug application in the second half of 2026 and expects pivotal Phase 2b lupus data in the third quarter. Alumis raised $345 million in January and held $308.5 million in cash at year-end, despite posting a $243 million net loss.